Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France - Full Text View

Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France (SISTOLA)

This study is ongoing, but not recruiting participants.

First Received: May 15, 2008 Last Updated: October 29, 2009 History of Changes

Sponsor:	AstraZeneca
Collaborator:	Takeda Global Research & Development Center, Inc.
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00679640

Purpose

The purpose of this study is to describe the way candesartan is used in heart failure treatment in France (treatment initiation and monitoring), treatment stops occurrence and reasons for and patients clinical evolution

Condition	Intervention
Heart Failure Cohort Study	Drug: Candesartan

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France

Resource links provided by NLM:

MedlinePlus related topics: Heart Failure

Drug Information available for: CV 11974 Candesartan cilexetil

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Profile of patients treated with candesartan for heart failure [ Time Frame: At inclusion ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Percentage of patients taking correctly its treatment : indication, contraindication, drug titration, treatment monitoring [ Time Frame: 6 and 12 months after ] [ Designated as safety issue: No ]
Percentage of patients stopping its treatment and reasons why [ Time Frame: 12 months after ] [ Designated as safety issue: No ]
Percentage of hospitalisations due to heart failure and cardiovascular deaths [ Time Frame: 12 months after ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	450
Study Start Date:	January 2008

Groups/Cohorts	Assigned Interventions
1 Outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure	Drug: Candesartan Oral tablets

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Patients seen in outpatient care (private consultation or outpatient hospital consultation) at the baseline visit

Criteria

Inclusion Criteria:

outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure

Exclusion Criteria:

patients included in a clinical trial the last 30 days before consultation
patients unable to answer the questions for linguistic or cognitive reasons
patients who will be difficult to follow during the one year study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00679640

Show 112 Study Locations

Sponsors and Collaborators

AstraZeneca

Takeda Global Research & Development Center, Inc.

Investigators

Principal Investigator:	Stephane Bouee, MD, MSc	CEMKA EVAL - Bourg La Reine - France
Study Chair:	Luc Hittinger, MD, Prof	Hôpital Henri Mondor - Service de cardiologie - Créteil - France

More Information

No publications provided

Responsible Party:	Astrazeneca ( Deborah Watts )
Study ID Numbers:	NIS-CFR-ATA-2007/1
Study First Received:	May 15, 2008
Last Updated:	October 29, 2009
ClinicalTrials.gov Identifier:	NCT00679640 History of Changes
Health Authority:	France: Haute Autorité de Santé Transparency Commission

Keywords provided by AstraZeneca:

candesartan
heart failure
cohort study
France

Additional relevant MeSH terms:

Angiotensin II Type 1 Receptor Blockers
Candesartan cilexetil
Heart Failure
Heart Diseases
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses

Candesartan
Cardiovascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 08, 2010